NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...
3d
Nektar Therapeutics ( NASDAQ:NKTR ) investors will be delighted, with the company turning in some strong numbers ...
Nektar Therapeutics ( (NKTR) ) has released its Q3 earnings. Here is a breakdown of the information Nektar Therapeutics presented to its ...
AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...
5d
Nektar Therapeutics (NKTR) extends its cash runway into 2026 with strategic divestitures, despite ongoing financial ...
Nektar Therapeutics today reported financial results for the third quarter ended September 30, 2024. Cash and investments ...
SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Thursday reported a loss of $37.1 million in its third quarter. On a per-share basis, the San Francisco-based company said it ...
Therapeutics and collaborators at The University of Texas MD Anderson Cancer Center presented late-breaking results from a Phase ...
Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback